Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines

Juan Carlos Tejedor, Jerzy Brzostek, Ryszard Konior, Detlef Grunert, Devayani Kolhe, Yaela Baine, Marie Van Der Wielen, Juan Carlos Tejedor, Jerzy Brzostek, Ryszard Konior, Detlef Grunert, Devayani Kolhe, Yaela Baine, Marie Van Der Wielen

Abstract

We evaluated antibody persistence in children up to 5 years after administration of a combined Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C (MenC)-tetanus toxoid (TT) conjugate vaccine coadministered with a pneumococcal conjugate vaccine. This is the follow-up study of a randomized trial (ClinicalTrials.gov registration no. NCT00334334/00463437) in which healthy children were vaccinated (primary vaccinations at 2, 4, and 6 months of age and booster vaccination at 11 to 18 months of age) with Hib-MenC-TT or a control MenC conjugate vaccine, coadministered with diphtheria-tetanus-acellular pertussis (DTPa)-based combination vaccines (DTPa/Hib for control groups) and a pneumococcal conjugate vaccine (10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine [PHiD-CV] or 7-valent cross-reacting material 197 [CRM197] conjugate vaccine [7vCRM]). MenC antibody titers were measured with a serum bactericidal antibody (SBA) assay using rabbit complement (i.e., rabbit SBA [rSBA]), and antibodies against Hib polyribosylribitol phosphate (PRP) were measured with an enzyme-linked immunosorbent assay. Antibody persistence up to 5 years after booster vaccination is reported for 530 children ∼6 years of age. The percentages of children with seroprotective rSBA-MenC titers were between 24.2% and 40.1% in all groups approximately 5 years after booster vaccination. More than 98.5% of children in each group retained seroprotective anti-PRP concentrations. No vaccine-related serious adverse events and no events related to a lack of vaccine efficacy were reported. Approximately 5 years after booster vaccination, the majority of children retained seroprotective anti-PRP antibody concentrations. The percentage of children retaining seroprotective rSBA-MenC titers was low (≤40%), suggesting that a significant proportion of children may be unprotected against MenC disease. (This study has been registered at ClinicalTrials.gov under registration no. NCT00891176.).

Copyright © 2016 Tejedor et al.

Figures

FIG 1
FIG 1
Disposition of study children and reasons for exclusion from according-to-protocol (ATP) cohorts for persistence at 24, 36, and 60 months after booster vaccination. N, number of study participants for the specified group.

References

    1. Lee CJ, Lee LH, Koizumi K. 2002. Polysaccharide vaccines for prevention of encapsulated bacterial infections: part 1. Infect Med 19:127–133.
    1. Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Safadi MA. 2012. The changing and dynamic epidemiology of meningococcal disease. Vaccine 30(Suppl 2):B26–B36. doi:10.1016/j.vaccine.2011.12.032.
    1. Peltola H. 2000. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13:302–317. doi:10.1128/CMR.13.2.302-317.2000.
    1. Pichichero ME. 2009. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 124:1633–1641. doi:10.1542/peds.2008-3645.
    1. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. 2006. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 194:1745–1752. doi:10.1086/509619.
    1. European Centre for Disease Prevention and Control. 2012. Surveillance of invasive bacterial diseases in Europe, 2012. European Centre for Disease Prevention and Control, Stockholm, Sweden: .
    1. Grupo de Trabajo MenCC. 2012. Revisión del programa de vacunación frente a enfermedad meningocócica por serogrupo C. Ministerio de Sanidad, Servicios Sociales e Igualdad, Madrid, Spain: .
    1. Hellenbrand W, Elias J, Wichmann O, Dehnert M, Frosch M, Vogel U. 2013. Epidemiology of invasive meningococcal disease in Germany, 2002–2010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect 66:48–56. doi:10.1016/j.jinf.2012.09.008.
    1. Skoczynska A, Wasko I, Kuch A, Kadlubowski M, Golebiewska A, Forys M, Markowska M, Ronkiewicz P, Wasiak K, Kozinska A, Matynia B, Hryniewicz W. 2013. A decade of invasive meningococcal disease surveillance in Poland. PLoS One 8:e71943. doi:10.1371/journal.pone.0071943.
    1. Miller JM, Mesaros N, Van Der Wielen M, Baine Y. 2011. Conjugate meningococcal vaccines development: GSK biologicals experience. Adv Prev Med 2011:846756. doi:10.4061/2011/846756.
    1. Pace D, Snape M, Westcar S, Hamaluba M, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ. 2007. A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr Infect Dis J 26:1057–1059. doi:10.1097/INF.0b013e31813429fa.
    1. Schmitt HJ, Maechler G, Habermehl P, Knuf M, Saenger R, Begg N, Boutriau D. 2007. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 14:426–434. doi:10.1128/CVI.00377-06.
    1. Tejedor JC, Moro M, Merino JM, Gomez-Campdera JA, Garcia-del-Rio M, Jurado A, Diez-Delgado FJ, Omenaca F, Garcia-Sicilia J, Ruiz-Contreras J, Martin-Ancel A, Roca J, Boceta R, Garcia-Corbeira P, Maechler G, Boutriau D. 2008. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13–14 months of age with antibody persistence up to 31 months of age. Pediatr Infect Dis J 27:579–588. doi:10.1097/INF.0b013e31816b4561.
    1. Pace D, Snape M, Westcar S, Oluwalana C, Yu LM, Begg N, Wysocki J, Czajka H, Maechler G, Boutriau D, Pollard AJ. 2008. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child 93:963–970. doi:10.1136/adc.2007.136036.
    1. Habermehl P, Leroux-Roels G, Sanger R, Machler G, Boutriau D. 2010. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12–18 months of age. Hum Vaccin 6:640–651. doi:10.4161/hv.6.8.12154.
    1. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. 2009. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 28:S97–S108. doi:10.1097/INF.0b013e318199f61b.
    1. Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L. 2009. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Pediatr Infect Dis J 28:S77–S88. doi:10.1097/INF.0b013e318199f609.
    1. Carmona A, Miranda M, Barrio F, De Vicente A, Mares J, Munoz E, Diez-Delgado J, Alonso A, Gimenez-Sanchez F, Merino J, Garcia-Corbeira P, Maechler G, Boutriau D. 2010. Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine. Pediatr Infect Dis J 29:269–271. doi:10.1097/INF.0b013e3181c15977.
    1. Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, Stapley L, England A, Findlow J, Miller E. 2010. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 17:154–159. doi:10.1128/CVI.00384-09.
    1. Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D. 2011. Immediate and longer term immunogenicity of a single dose of the combined Haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J 30:340–342. doi:10.1097/INF.0b013e31820013d2.
    1. Omenaca F, Aristegui J, Tejedor JC, Moreno-Perez D, Ruiz-Contreras J, Merino JM, Muro Brussi M, Sanchez-Tamayo T, Castro Fernandez J, Cabanillas L, Peddiraju K, Mesaros N, Miller JM. 2011. Combined Haemophilus influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines. Pediatr Infect Dis J 30:e216–e224. doi:10.1097/INF.0b013e3182293a82.
    1. Khatami A, Snape MD, John T, Westcar S, Klinger C, Rollinson L, Boutriau D, Mesaros N, Wysocki J, Galaj A, Yu LM, Pollard AJ. 2011. Persistence of immunity following a booster dose of Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatr Infect Dis J 30:197–202. doi:10.1097/INF.0b013e3181f728fd.
    1. Tejedor JC, Merino JM, Moro M, Navarro ML, Espin J, Omenaca F, Garcia-Sicilia J, Moreno-Perez D, Ruiz-Contreras J, Centeno F, Barrio F, Cabanillas L, Muro M, Esporrin C, De Torres MJ, Caubet M, Boutriau D, Miller JM, Mesaros N. 2012. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 31:1074–1077. doi:10.1097/INF.0b013e318269433a.
    1. Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Stoney T, Heron L, Lambert S, Mesaros N, Peddiraju K, Miller JM. 2013. Three-year antibody persistence and safety after a single dose of combined Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatr Infect Dis J 32:169–174. doi:10.1097/INF.0b013e3182787bff.
    1. Khatami A, Snape MD, Ohene-Kena B, Young K, Oeser C, Michaelis LJ, Macleod E, Smee H, Van Der Meeren O, Leyssen M, Caubet M, Yu LM, Heath PT, Faust SN, Finn A, Pollard AJ. 2013. Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants. Pediatr Infect Dis J 32:675–681. doi:10.1097/INF.0b013e31828672a7.
    1. Vesikari T, Forsten A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. 2013. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J 32:521–529. doi:10.1097/INF.0b013e31827e22e3.
    1. Booy R, Nolan T, Reynolds G, Richmond P, Nissen M, Marshall H, Stoney T, Van Der Wielen M, Kolhe D, Miller JM. 2015. Five-year antibody persistence and safety after a single dose of combined Haemophilus influenzae type B Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Haemophilus influenzae type b-primed toddlers. Pediatr Infect Dis J 34:1379–1384. doi:10.1097/INF.0000000000000898.
    1. Dagan R, Poolman J, Siegrist CA. 2010. Glycoconjugate vaccines and immune interference: a review. Vaccine 28:5513–5523. doi:10.1016/j.vaccine.2010.06.026.
    1. Slack MH, Schapira D, Thwaites RJ, Burrage M, Southern J, Andrews N, Borrow R, Goldblatt D, Miller E. 2001. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. J Infect Dis 184:1617–1620. doi:10.1086/324666.
    1. Andrews N, Borrow R, Miller E. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 10:780–786. doi:10.1128/CDLI.10.5.780-786.2003.
    1. Kayhty H, Peltola H, Karanko V, Makela PH. 1983. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147:1100. doi:10.1093/infdis/147.6.1100.
    1. Anderson P. 1984. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149:1034–1035. doi:10.1093/infdis/149.6.1034.
    1. Immunization Practices Advisory Committee. 1991. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 40(RR-13):1–19.
    1. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. 2009. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J 28(Suppl):S109–S118. doi:10.1097/INF.0b013e318199f62d.
    1. National Health Service. 2014. The NHS vaccination schedule. .
    1. Lechevin I, Le Bras V, Lestrate PR, Wauters D. 2012. Identification of key parameters that impact the sensitivity of the MenC-rSBA assay to natural antibodies, abstr P 145. Programme XVIIIth Int Pathogenic Neisseria Conf, Würzburg, Germany, 9 to 14 September.
    1. Joint Committee on Vaccination and Immunisation. 2012. JCVI statement on the use of meningococcal C vaccines in the routine childhood immunisation programme. Joint Committee on Vaccination and Immunisation, London, United Kingdom. .
    1. Diez-Domingo J, Cantarino MV, Torrenti JM, Sansano MI, Rosich AJ, Merino AH, de Miguel AG, Gonzalez JB, Marcos MD. 2010. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J 29:148–152. doi:10.1097/INF.0b013e3181b9a831.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel